Inclusion Criteria:
  -  Subjects must give written, signed and dated informed consent
  -  Confirmed diagnosis of PMM according to the 2016 Rome Consensus recommendations
  -  Confirmed mitochondrial mutation with evidence of myopathy
  -  Able to remain on stable medication throughout the study
Exclusion Criteria:
  -  Documented evidence of ongoing rhabdomyolysis
  -  Subjects with motor abnormalities other than related to mitochondrial disease
  -  Treatment with an investigational drug within 3 months prior to Day 1
  -  Hospitalised within 3 months prior to screening for any major medical condition
  -  Pregnant or nursing females